Dotatate gallium Ga-68
Also known as: 68Ga-DOTATATE, 68Ga‑DOTATATE, DOTA-Tyr3-octreotate Ga-68, DOTA‑TATE, Ga-68 DOTATATE, gallium-68 dotatate, Netspot
Source Dotatate gallium Ga-68 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
68Ga‑DOTATATE is a gallium‑68 labeled somatostatin analog used for PET/CT imaging of SSTR2‑expressing neuroendocrine tumors.
Mechanism of Action
High‑affinity binding to somatostatin receptor subtype 2 (SSTR2) leading to cellular uptake of the Ga‑68 label for PET imaging.
Routes of Administration
Goals & Uses
- Staging and restaging of NETsDiagnostic OncologyHigh
- Localization of somatostatin receptor-positive neuroendocrine tumorsDiagnostic ImagingHigh
- Monitoring response to somatostatin analogue therapyTreatment MonitoringModerate
- Detection of occult primary NETDiagnostic ImagingModerate
- Patient selection for PRRT (peptide receptor radionuclide therapy)Treatment PlanningHigh
- Detect and stage somatostatin receptor‑positive neuroendocrine tumorsDiagnostic ImagingHigh
Contraindications
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- BreastfeedingPopulationModeratePotential transfer into breast milk or insufficient safety data
- Known hypersensitivity to DOTATATE or any excipientAllergyHigh
- Hypersensitivity to dotatate or any component of the formulationAllergyHigh
Adverse Effects
- Radiation exposureRadiologicalCommon
- Injection site painLocalCommonPain at the injection site
- Hypersensitivity/anaphylaxisImmunologicalRare
- Injection site pain/irritationLocalUncommon
- Hypersensitivity reactionImmunologicRare
- FlushingVascularUncommonWarmth and redness of the skin
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
Drug Interactions
- Long-acting somatostatin analogues (e.g., octreotide LAR, lanreotide)Moderate
- none identifiedLow
- Short-acting octreotideLow
Population Constraints
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Pregnant womenReproductiveAbsolute
- Pediatric patients <2 yearsAgeRelative
Regulatory Status
- European UnionApprovedApproved: Imaging of somatostatin receptor‑positive neuroendocrine tumorsApproved under EU regulatory framework.
- United StatesApprovedApproved: Imaging of somatostatin receptor‑positive neuroendocrine tumorsApproved as NETSPOT.
- United KingdomApprovedApproved: Imaging of somatostatin receptor‑positive neuroendocrine tumorsApproved by MHRA.
FDA‑approved (NETSPOT) for diagnostic imaging of somatostatin receptor‑positive neuroendocrine tumors.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Dotatate gallium Ga-68?
68Ga‑DOTATATE is a gallium‑68 labeled somatostatin analog used for PET/CT imaging of SSTR2‑expressing neuroendocrine tumors.
What is Dotatate gallium Ga-68 used for?
Dotatate gallium Ga-68 is educationally associated with: Staging and restaging of NETs, Localization of somatostatin receptor-positive neuroendocrine tumors, Monitoring response to somatostatin analogue therapy, Detection of occult primary NET, Patient selection for PRRT (peptide receptor radionuclide therapy), Detect and stage somatostatin receptor‑positive neuroendocrine tumors. Educational only — not medical advice.
How is Dotatate gallium Ga-68 administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Dotatate gallium Ga-68?
Reported adverse effects include: Radiation exposure, Injection site pain, Hypersensitivity/anaphylaxis, Injection site pain/irritation, Hypersensitivity reaction, Flushing, Nausea. This list is not exhaustive — consult a qualified clinician.
Who should avoid Dotatate gallium Ga-68?
Recorded contraindications: Pregnancy, Breastfeeding, Known hypersensitivity to DOTATATE or any excipient, Hypersensitivity to dotatate or any component of the formulation. Consult a qualified clinician before use.